2034년까지 외래 환자 대상 정맥 주입 치료 서비스 시장 규모, 점유율 및 수요

외래 수액 치료 서비스 시장은 2025년 303억 1천만 달러 규모였으며, 2026년부터 2034년까지 연평균 7.66%의 성장률을 기록하며 2034년에는 547억 3천만 달러에 이를 것으로 예상됩니다. 이러한 성장은 대체 의료 서비스 제공 방식의 증가, 비용 효율적인 의료 서비스를 선호하는 의료비 지불자의 추세, 그리고 외래 수액 치료가 의료계에서 점차 수용되고 있는 추세를 반영합니다.

북미는 특수 의약품 사용, 보험사의 진료 현장 최적화, 광범위한 의료 네트워크 덕분에 여전히 가장 발전된 지역입니다. 이 지역의 외래 주입 치료 서비스 시장 규모는 만성 질환 유병률 증가, 바이오시밀러 도입, 종양학 보조 치료, 면역학 치료, 외래 환자 접근성 향상을 위한 운영 투자에 힘입어 2026년부터 2034년까지 연평균 7.3~7.8% 성장할 것으로 예상됩니다.

외래 환자 대상 정맥 주입 치료 서비스 시장 평가 및 분석

Scheduling, prior authorization electronically, cold chain, and remote nurse documentation are some ways that infusion capacity planning is being revolutionized by technology. Providers have changed their focus from episodic chair utilization to disease-based programs including immunology, neurology, gastroenterology, oncology support services, and nutrition therapies. This is due to production issues, which are related to biologics, requiring compounding, skilled nurses, adverse event policies, and payer validation. This operational complexity strengthens established networks within Ambulatory Infusion Therapy Services Market.

Future demand is likely to expand to suburban cluster areas, secondary markets, and specialty pharmacies' neighboring clinics. Outpatient regulation, biosimilar substitution policy, and hospitals’ lack of space are driving the business case for decentralized infusion suites. Future markets will probably focus on oncology, immunology, gastroenterology, and post-acute antibiotics programs. The Ambulatory Infusion Therapy Services Market will more and more reward providers that can integrate clinical safety, payer contracts, patient intake digitally, and nurse supply reliably. 

Ambulatory Infusion Therapy Services Market Report Scope

Ambulatory Infusion Therapy Services Market Analysis

Demand has been increasing due to the need for repeated biologics and immune globulins administration because of the prevalence of auto-immune, neurological, gastroenterological, and immunodeficiency diseases. Ambulatory Infusion Therapy Services Market is also influenced by the preference of payers for low-acuity, observed environments rather than hospital outpatient clinics. The ecosystem connects drug manufacturers, specialty pharmacies, prescribers, payers, nurses, accreditation agencies, and logistics providers to form a service chain.

Supply is limited by the number of available infusion nurses, reimbursement policies, and needs for the drugs handling. Companies having standardized protocols will be able to increase chair turnaround, cancel fewer visits, and avoid emergency situations. Hospitals will have advantages of clinical governance whereas free-standing sites – due to their convenience and reduced costs. Such equilibrium will promote the creation of hybrid models having centralized pharmacy and decentralized access points.

The competition in this market is fractured yet more strategic. The Ambulatory Infusion Therapy Services Market analysis reveals national-level companies such as Option Care Health Inc., UnitedHealth Group Incorporated via its Optum business line, Coram LLC, Accredo Health Group Inc., KabaFusion Holdings LLC, and Soleo Health Inc. in competition with hospitals like Cleveland Clinic Foundation, HCA Healthcare Inc., CHI Health, and McLaren Health Care Corporation.

Money is being invested in areas of referral automation, payer contracting, reporting, and specialization rather than merely expanding site locations. PharMerica Corporation continues to play a role in situations that involve the intersection between long-term care pharmacy services and infusion care. Competitive advantage in the market is based on treatment breadth, geographical presence, nurse staffing flexibility, and capability in proving results to payers.

Ambulatory Infusion Therapy Services Market:

요구 사항에 맞게 이 보고서를 사용자 정의하십시오.

이 보고서의 일부, 국가 수준 분석, Excel 데이터 팩을 포함하여 모든 보고서에 대한 사용자 정의를 무료로 받을 수 있을 뿐만 아니라 스타트업 및 대학을 위한 훌륭한 제안 및 할인을 이용할 수 있습니다

무료 사용자 정의 받기

외래 주입 요법 서비스 시장: 전략적 통찰력

• 이 보고서의 주요 주요 시장 동향을 확인하세요.
  이 무료 샘플에는 시장 동향부터 추정 및 예측에 이르기까지 데이터 분석이 포함됩니다.

무료 샘플 PDF

Regional Insights

North America Ambulatory Infusion Therapy Services Market

North America held 47–49% share in 2025 and is projected to expand at a CAGR of 7.3–7.8% during 2026–2034. The Ambulatory Infusion Therapy Services Market share is supported by mature specialty pharmacy networks, broad biologics utilization, and reimbursement models that encourage site-of-care migration. Accreditation standards, analytics by payers, and manufacturers who desire reliable delivery mechanisms for their premium products are advantages for this region.

There are structural demands resulting from aging population, high number of treatments available for autoimmune diseases, oncology support care requirements, and high use of biosimilars. Although the US dominates volumes in the region, Canada is known to contribute through the outpatient care offered by hospitals and province level care redesign. The providers are working on integrating patient intake, solutions for nurse productivity, and adverse events preparation because the payer now assesses total episode costs, compliance, and adherence. 

U.S. Ambulatory Infusion Therapy Services Market

The US held the share of 82-85% in North America in 2025 and is anticipated to register a growth rate of 7.2-7.7% in terms of CAGR during 2026-2034. Some commercial payers are moving some of the biologic infusions from the hospital outpatient department settings, where possible, and when the patient acuity can support that.

Companies have more presence in the metropolitan locations of large or mid-size. These are companies such as Option Care Health Inc., Coram LLC, Accredo Health Group Inc., UnitedHealth Group Incorporated, KabaFusion Holdings LLC, and Soleo Health Inc., which work in conjunction with hospitals. There are many applications, and some of them are immunoglobulin, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, parenteral nutrition, and anti-infective.

Europe Ambulatory Infusion Therapy Services Market

Europe held 24%–26% market share in 2025 and is anticipated to grow at a CAGR of 6.8%–7.3% between 2026 and 2034. Germany is the market leader due to good match of prescription practice, biologic access, and outpatient care infrastructure with infusions. The UK is increasing community infusion capacity in response to pressures on hospitals from the NHS to relieve their backlog. Private sector facilities provide rapid access to certain treatments.

Germany has good hospital infrastructure, specialty doctor availability, and experience with biosimilars in immuno-oncology support. France, Italy, and Spain are developing their market through regional outpatient care programs. However, the reimbursement process varies. Infusion suite adoption occurs where public health authorities see it as a solution to increase capacity. Growth is stable but not disruptive as it depends on governance, nursing, and purchasing policies.

APAC Ambulatory Infusion Therapy Services Market

The APAC region has a market share ranging between 17-19% and has the highest rate of expansion, growing at a CAGR of 8.6-9.2% in 2026-2034 owing to its fast-pace development. China dominates the market by volume due to the decentralization of certain recurring treatments by tertiary hospitals, while Japan and South Korea have outpatient systems that offer quality services and are regulated.

India and Australia are developing ambulatory infrastructure in terms of private hospitals, health insurance, and specialty clinics. The policy focus on congestion in hospitals, production of local biologics, access to oncology, and health records digitization favors uptake. The industrial factors driving growth in the market include cold chain investments and clinic networks as well as physicians’ involvement in the management of chronic conditions.

Middle East & Africa Ambulatory Infusion Therapy Services Market

The Middle East & Africa is projected to grow at a CAGR of 7.9–8.5% during 2026–2034. Saudi Arabia is the leading country because healthcare transformation programs are expanding outpatient infrastructure, specialty hospitals, and private-sector participation. The UAE follows with medical tourism, premium clinics, and payer interest in efficient day-care delivery.

The South African contribution is seen in terms of private hospitals and oncology infusions while the Rest of MEA continues to have mixed results owing to staffing and compensation issues. Public investments in energy-based health infrastructure development in the Gulf region makes the region more prepared for the infusion suites and specialist drug distribution.

Segmentation Analysis

Type

The Type segment is projected to grow at a CAGR of 7.4–7.9% during 2026–2034. The Ambulatory Infusion Therapy Services Market scope across type is shaped by clinical acuity, payer steering, patient convenience, and provider ownership models. Hospital-based centers remain important for complex patients, while free-standing centers are gaining traction where predictable therapies can be administered safely in lower-cost, accessible environments.

• Hospital-Based Ambulatory Surgery Centers: These centers retain a leading position because hospitals control referrals, pharmacy oversight, emergency escalation, and specialist coordination for higher-risk cases requiring closer supervision.
• Free-Standing Ambulatory Surgery Centers: These centers are strategically important for community access, payer-preferred care pathways, lower facility costs, and recurring therapies suited to standardized monitoring outside hospital campuses.

Specialty

The Specialty segment is projected to expand at a CAGR of 7.1–7.6% during 2026–2034. Specialty configuration influences referral capture, staff utilization, and therapy breadth. Single-specialty models deliver disease-program depth, while multi-specialty centers improve chair utilization across immunology, gastroenterology, neurology, orthopedic supportive care, ophthalmology-related procedures, and endoscopic care pathways supported by outpatient medication administration.

• Single- Specialty Centers: These centers are positioned around focused disease expertise, physician trust, protocol consistency, and improved patient education for therapies requiring frequent monitoring or complex adherence support.
• Multi-Specialty Centers: These centers support higher operating flexibility by combining several referral streams, reducing idle capacity, and enabling broader payer contracting across multiple recurring therapy categories.

Treatment

The Treatment segment is forecast to grow at a CAGR of 7.5–8.0% during 2026–2034. Treatment demand is shaped by procedure volumes, chronic disease prevalence, recovery protocols, and outpatient suitability. Cataract, orthopedic, endoscopic, and gastroenterology-related services benefit from shorter treatment cycles, better scheduling systems, and physician comfort with structured ambulatory pathways that reduce inpatient dependence.

• Cataract Surgery: Cataract procedures maintain strong ambulatory relevance because they are high-volume, protocol-driven, lower-acuity services suited to efficient scheduling and predictable post-procedure monitoring.
• Orthopaedic Surgery: Orthopedic pathways are important as joint, sports injury, and pain-related procedures shift toward day-care models supported by anesthesia advances and recovery protocols.
• Endoscopic Procedure: Endoscopic procedures support consistent outpatient throughput because they require defined preparation, short recovery windows, and specialist-led workflows that fit ambulatory capacity planning.
• Gastroenterology: Gastroenterology is strategically significant due to inflammatory bowel disease biologics, recurring monitoring needs, and growing physician preference for controlled outpatient administration settings.

Opportunity Snapshot

Ambulatory Infusion Therapy Services Market Growth Drivers and Impact Analysis

Shift from Hospital Outpatient Departments to Lower-Cost Sites

The payer's push towards the examination of sites-of-care regarding biologics, immunoglobulins, and other repeat infusions stems from the high associated costs of facilities at the hospital's outpatient department. This is a significant market driver since it leads to the channeling of eligible patients to ambulatory suites, specialty pharmacies, and adjacent-to-home care options where safety standards are met. Providers who are quick in gaining approval, have proper reimbursement documentation, and adverse event process are capable of attracting greater referrals. The market driver is not just about cutting down on costs but making hospital chairs available for complex cases.

Rising Specialty Drug Utilization Across Chronic Diseases

The increase in infused and injectable specialty drug therapies is creating increased needs for recurrent administrations in immunology, neurology, oncology supportive care, gastroenterology, and orphan diseases. Such therapies often need to be refrigerated, doses validated, monitored, and administered by a nurse practitioner, which makes an organized ambulatory environment preferable to scattered office administration. This effect is evident in the growth in need for disease-specific guidelines, pharmacy integration, and assistance from manufacturers. Those who are able to handle complicated onboarding, benefit research, and patient education shorten the delay in starting the therapies. The rise of biologics and biosimilars provides volume growth for the Ambulatory Infusion Therapy Services Market through patients who require scheduled therapy.

Digital Intake and Clinical Workflow Standardization

Efficiency in operations is increasing within infusion networks through such innovations as digital scheduling, integration with the EMR, automated prior authorization, and remote clinical documentation. They help to avoid administrative leakage, cancellations, and treatment delays, and this translates to increased efficiency in chair utilization and improved payer relationships. The benefits of workflow automation include enabling multi-site operations, which is a requirement when expanding provider networks and when introducing specialty drugs by manufacturers. The effect of these innovations on the market includes better margin management, as nursing, compounding, and inventory management can be optimized. Those who will manage to translate operational data into payer evidence will benefit from the evolving contracts.

Ambulatory Infusion Therapy Services Market Future Trends

Outcome-Linked Infusion Network Contracting

Contracting in the future would progress from merely the use of reimbursement rates to a more sophisticated network selection process, driven by the evidence gathered on factors such as adherence, adverse events handling, therapy completion, satisfaction and avoidable hospitalization. The Ambulatory Infusion Therapy Services market trends suggest that payers and manufacturers will be increasingly interested in these factors. The ability of infusion companies to collect more evidence at the point of care will be critical for future contracting and analysis of these events would be needed to convert them into actionable insights.

Expansion of Hybrid Infusion and Home-Adjacent Models

The hybrid models incorporating ambulatory suites, home infusion, telephone pharmacy services, and remote monitoring are likely to gain traction in the coming years. New patients who are going to receive high-risk medications could get the first doses in the monitored suites and then move to home or less intensive environments. Such an approach strikes a balance between convenience and safety while allowing healthcare professionals to manage their nursing staff better. Moreover, such models would be beneficial for providing access to healthcare services in rural and suburban areas where it might be impossible to establish fully-fledged specialty centers. 

Ambulatory Infusion Therapy Services Market Opportunities

Specialty Pharmacy and Ambulatory Suite Integration

A major opportunity lies in tighter integration between specialty pharmacy operations and ambulatory administration sites. Coordinated models can reduce therapy-start delays, improve inventory accuracy, support manufacturer requirements, and create a single accountability point for patients and prescribers. Ambulatory Infusion Therapy Services Market Forecasts indicate that operators investing in centralized intake, benefits verification, and suite scheduling will be better positioned to serve complex biologic launches. The opportunity is particularly attractive where immunology, gastroenterology, neurology, and rare disease therapies require recurring administration. Investors should prioritize platforms with proven payer relationships, scalable pharmacy infrastructure, and documented nursing governance.

Capacity Development in Secondary Urban Markets

Expanding into secondary urban markets represents an opportunity to capitalize on long-distance traveling times for recurring infusions among non-academic patients. The key lies in establishing smaller protocol suites located closer to specialist hubs, which would not only increase accessibility but also reduce unnecessary utilization of hospital outpatients. The best opportunity exists in the regions where commercial insurance, private hospital chains, and specialists of chronic conditions converge. The strategy includes designing a facility that is modular in nature, nursing hiring arrangements, and signing referral agreements with gastroenterologists, rheumatologists, neurologists, and oncologists.

Recent Developments

• September 2025: CVS Health Corporation launched CVS Infusion Care locations within selected retail stores, creating private infusion suites for eligible patients and expanding access to specialty infusion and injectable therapies. The company stated that seven locations opened in the first quarter of 2025 and reported 100% patient satisfaction for clinical nursing support in those suites
• August 2025: Option Care Health Inc. selected Option Care Health as specialty infusion therapy provider for administration of its lead asset eDSP, subject to clinical success and regulatory approval. The agreement leverages more than 90 full-service pharmacies and over 180 ambulatory infusion suites across the US to support rare disease commercialization and patient access
• August 2025: Nutrishare Inc. acquired select Coram pharmacy home infusion assets from CVS Health, supporting nationwide home total parenteral nutrition services and adding a new Arizona pharmacy. The transaction followed Coram’s move to close local pharmacies and establish three national hubs, reflecting ongoing restructuring in infusion service delivery

저자 소개 (생명과학 연구팀)

미리날 켈할카르

관리자,
연구 및 컨설팅

Mrinal은 생명 과학 시장 정보 분석 및 컨설팅 분야에서 8년 이상의 경력을 보유한 노련한 리서치 분석가입니다. 전략적 사고방식과 탁월함을 향한 확고한 의지를 바탕으로 제약 예측, 시장 기회 평가, 업계 벤치마크 개발 분야에서 심도 있는 전문 지식을 쌓아 왔습니다. 그녀의 업무는 고객이 정보에 기반한 전략적 의사 결정을 내릴 수 있도록 실질적인 통찰력을 제공하는 데 중점을 두고 있습니다.

Mrinal의 핵심 강점은 복잡한 정량적 데이터 세트를 의미 있는 비즈니스 인텔리전스로 변환하는 것입니다. 그녀의 분석적 통찰력은 제약 및 의료기기 분야의 시장 진출(GTM) 전략을 수립하고 성장 기회를 발굴하는 데 중요한 역할을 합니다. 신뢰할 수 있는 컨설턴트로서, 그녀는 고객의 워크플로 프로세스를 간소화하고 모범 사례를 구축하는 데 지속적으로 집중하여 혁신과 운영 효율성을 향상시킵니다.

사용 후기

Insight Partners의 SCADA 시스템 시장 보고서는 포괄적이며, 현재 동향과 미래 전망에 대한 귀중한 통찰력을 제공합니다. 팀은 매우 전문적이고, 신속하게 대응하며, 처음부터 끝까지 지원해 주었습니다. 저희는 매우 만족하며 Insight Partners의 서비스를 적극 추천합니다.

란 케뎀 파트너, Reali Technologies LTDs

아주 구체적인 소프트웨어 시장에 대한 보고서를 요청했는데, 팀에서 며칠 만에 보고서를 작성해 주셨습니다. 정보는 매우 관련성이 높고 잘 정리되어 있었습니다. 그 후 보고서에 몇 가지 수정과 추가 사항을 요청했습니다. 팀원들의 응답도 매우 빨랐고, 일주일도 채 되지 않아 최종 보고서를 받았습니다.

장-에르브 젠 의장, 퓨처 애널리티카

The Insight Partners와 함께 중요한 시장 조사 및 예측 작업을 진행했습니다. Insight Partners는 기회와 위험에 대한 명확한 통찰력을 제공하여 계획을 세우는 데 큰 도움이 되었습니다. The Insight Partners의 조사는 사용하기 쉬웠고, 탄탄한 데이터를 기반으로 했습니다. 덕분에 현명하고 자신 있는 결정을 내릴 수 있었습니다. The Insight Partners를 강력 추천합니다.

피유시 나그팔 수석 부사장, 하이빔 글로벌

Insight Partners는 탄탄한 분야 전문성을 바탕으로 통찰력 있고 체계적인 시장 조사를 제공했습니다. Insight Partners 팀은 처음부터 끝까지 전문적이고 신속하게 대응했습니다. 사용자 친화적인 웹사이트 덕분에 업계 보고서에 쉽게 접근할 수 있었습니다. 신뢰할 수 있고 고품질의 조사 서비스를 원하신다면 Insight Partners를 강력 추천합니다.

아다치 유키히코 대표이사, 딥블루 주식회사

The Insight Partners에서 시장 보고서를 구매한 것은 이번이 처음입니다. 처음에는 확신이 없었지만, 웹사이트를 방문하고 나서 위험을 감수하고 시장 보고서를 구매하는 것이 더 편하다는 것을 알게 되었습니다. 보고서의 품질과 고객 서비스에 매우 만족합니다. 처음 보고서를 보고 몇 가지 질문과 의견이 있었지만, 분석가와 이메일로 몇 차례 대화를 나눈 후, 전략 기획 과정에 참고할 수 있는 보고서를 확보했다고 생각합니다. 시간을 내어 긍정적인 경험을 선사해 주셔서 정말 감사합니다. 다른 사람들에게도 귀사의 서비스를 적극 추천할 것이며, 추가적인 시장 데이터가 필요할 때면 가장 먼저 귀사에 연락하겠습니다.

존 스즈키 사장 겸 최고 경영자, 이사회 이사, BK 테크놀로지스

나이지리아 감염성 질환 IVD 시장 관련 정보 요청에 응해 주신 귀사의 지원과 전문성에 감사드립니다. 귀사의 인내심과 지도, 그리고 할인 혜택을 기꺼이 제공해 주셔서 결국 계약을 성사시킬 수 있었습니다. 첫 만남을 통해 귀사가 저에게 심어주신 좋은 인상을 바탕으로 앞으로도 The Insight Partners와 함께할 수 있기를 기대합니다.

치지오케 박사 오니아 전무이사, 파인크레스트 헬스케어 유한회사

Previous Next